ClinicalTrials.gg
RecruitingNCT05484973Updated Oct 22, 2026

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

An interventional study of AMMA Portalbe Scalp Cooling System in Alopecia, Chemotherapy-induced Alopecia and Hair Loss, sponsored by Cooler Heads Care Inc.. Recruiting at 2 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cooler Heads Care Inc. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
42nd of 204
99 · median 40
Started
2024
with 19 others
No phase
93 of 217
24 open now
Primary completion
2027-06
later than 39 of 62 live
Registered
147th of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 42nd largest by planned enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2024, is one of 93 with no phase, reaches primary completion later than 39 of the 62 other live ones, and was the 147th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.

Read the detailed description

This is a prospectively enrolling, post-market, on-label study to assess the ability of the AMMA PSCS to prevent hair loss in women receiving CT for early-stage breast cancer, and to assess the safety, tolerability and compliance, patient quality of life, and satisfaction with hair after treatment. Female patients at least 21 years of age with stage I, II, or III breast cancer who are receiving a taxane-containing CT regimen that is scheduled to be completed within six months will be identified and data from the electronic health record (EHR) as well as prospective data will be collected.

AMMA is designed to be used by patients in the chemotherapy infusion center, during transport from the infusion center to home, and after arrival at home. Patients will participate in training in AMMA use and will be asked to bring the device to the chemotherapy infusion center for use during each chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy and for at least 2.5 hours after chemotherapy. Scalp photos will be obtained at baseline and after the last chemotherapy treatment.

03

Conditions studied

  • Alopecia
  • Chemotherapy-induced Alopecia
  • Hair Loss
  • Breast Cancer
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients ≥ 21 years of age
  2. Documented diagnosis of breast cancer, stage I, II, or III
  3. A planned taxane-containing CT regimen in the or neoadjuvant setting with curative intent
  4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and/or hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and/or hormonal therapy period
  5. Plan to complete the current CT regimen within six months
  6. At least two years out from the last CT causing hair loss with complete recovery of hair
  7. Karnofsky17 performance status 80% or greater
  8. Willing and able to sign for this study
  9. Willing and able to complete all required study procedures

Exclusion criteria

Exclusion Criteria:

  1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale
  2. disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others
  3. A history of whole brain radiation
  4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC/T, EC/T, TAC, etc.)
  5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted
  6. Current and/or prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique
  7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up
  8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens
  9. History of and/or current exposure to other agents, drugs, device, or procedure that may cause hair loss
  10. Cold sensitivity
  11. Intercurrent life-threatening
  12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism
  13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia
  14. Concurrent hematologic malignancy
  15. Participation in any other clinical investigation
  16. Concurrent treatment with any agent
  17. Any reason the investigator does not believe the patient is a good candidate for the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    All patients will use AMMA

    Device: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.

    Device: AMMA Portalbe Scalp Cooling System

Interventions

  • DeviceAMMA Portalbe Scalp Cooling System

    AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.

06

What researchers measure

Primary outcomes

  1. Hair Loss

    To evaluate hair loss as assessed by the investigator at 3 weeks (±1 week) after the completion of the last CT treatment/infusion visit using the Common Terminology Criteria for Adverse Events (CTCAE) post-treatment, by photographs, compared to baseline photographs.

    Time frame: 3 Weeks

Secondary outcomes

  1. Device-related adverse events

    To assess safety of the AMMA PSCS based on the occurrence of device-related adverse events, occurrence of scalp changes determined by physical examination, and patient symptoms with use of the PSCS.

    Time frame: 3 Weeks

  2. Scalp changes

    Occurrence of scalp changes in patients during and after use of the AMMA PSCS.

    Time frame: 3 Weeks

  3. Patient symptoms

    Patient symptoms reported during use of the AMMA PSCS as recorded by a symptom survey following each infusion session.

    Time frame: 3 Weeks

  4. Subject's tolerability

    Subject's tolerability of AMMA PSCS treatment demonstrated by responses to questions related to tolerability.

    Time frame: 3 Weeks

  5. Patient assessment of hair loss

    Patient assessment of hair loss as recorded in the Alopecia Self-Report Survey at post-treatment follow-up according to the following scale: \<50% of normal for the patient, or ≥50% hair loss.

    Time frame: 3 Weeks

  6. Patient satisfaction and QoL - Body Image Scale (BIS)

    Patient satisfaction and QoL as assessed by the BIS at baseline and posttreatment follow-up. The 10-item Body Image Scale was developed by Hopwood et al. in 2001 to measure affective, behavioral, and cognitive body image symptoms. Patients can indicate body image symptoms on a 4-point scale (0 "not at all" to 3 "very much"). The total score ranges from 0 to 30 and can be calculated by summing up the 10 items. A higher score means a higher level of body image disturbance

    Time frame: 3 Weeks

  7. Patient satisfaction and QoL - European Organization for Research and Treatment (EORTC) QLQ-BR23

    Patient satisfaction and QoL as assessed by the EORTC's QLQ-BR23 at baseline and post-treatment follow-up. All scores are linearly transformed to a 0 to 100 scale. A high or healthy level of functioning is represented by a high functional score. A high QOL is represented by a high score for global health status or QOL. More severe symptoms or problems are represented by high symptom scores or items.

    Time frame: 3 Weeks

  8. Device success

    Device success is defined as ability to set up and use the AMMA device as instructed. This will be measured for each treatment and then for all treatments. If a study subject does not complete one or more of the CT visits, that does not constitute a device failure.

    Time frame: 3 Weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 31 months is above that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2026 → Jun 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2022
First posted
Aug 2, 2022
StartActual
Nov 8, 2024
Primary completionEst.
Jun 30, 2027was Mar 2026
CompletionEst.
Sep 30, 2027was Sep 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 31, 2026→Jun 30, 2027
Oct 22, 2026
Study completion
Sep 30, 2026→Sep 30, 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Mar 31, 2026→Jun 30, 2027
    Study completion Sep 30, 2026→Sep 30, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05484973
Lead sponsor
Cooler Heads Care Inc.
Responsible party
Sponsor
First posted
Aug 2, 2022
Start date
Nov 8, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Chris Schultz, BS
Contact
cschultz@ecr-inc.com
9715067552
Kate Dilligan
principal investigator · Cooler Heads Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion